Last reviewed · How we verify
Eupenta Inj.
Eupenta is a pentamidine-based antiprotozoal agent that disrupts parasite DNA and mitochondrial function.
Eupenta is a pentamidine-based antiprotozoal agent that disrupts parasite DNA and mitochondrial function. Used for Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Leishmaniasis, Trypanosomiasis.
At a glance
| Generic name | Eupenta Inj. |
|---|---|
| Sponsor | LG Chem |
| Drug class | Antiprotozoal agent |
| Target | Parasite DNA and mitochondrial function |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Pentamidine works by interfering with DNA synthesis and energy metabolism in protozoal parasites, particularly Pneumocystis jirovecii and Leishmania species. It accumulates in parasite mitochondria and nuclei, causing disruption of cellular respiration and nucleic acid synthesis, leading to parasite death.
Approved indications
- Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment
- Leishmaniasis
- Trypanosomiasis
Common side effects
- Hypoglycemia
- Nephrotoxicity
- Hypotension
- Pancreatitis
- Cardiac arrhythmias
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eupenta Inj. CI brief — competitive landscape report
- Eupenta Inj. updates RSS · CI watch RSS
- LG Chem portfolio CI